Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Novavax-Serum Institute Seal Win-Win Deal For COVID-19 Vaccine

50:50 Revenue Split In Licensed Regions

Executive Summary

Novavax has granted Serum Institute rights to develop, manufacture and commercialize its COVID-19 vaccine candidate in selected regions, in another endorsement of the Indian group's capabilities. The agreement, which expands on an earlier association, gives Serum exclusive marketing rights in India until the deal ends and non-exclusive rights for developing countries to the end of the pandemic, with the US firm getting half of net revenue.

You may also be interested in...



Coronavirus Update: BioNTech Gets €375m From Germany To Fund Vaccine

Plus: Valneva confirms supply deal with the UK government for its inactivated vaccine candidate; Humanigen expands manufacturing ahead of Phase III data.

Coronavirus Update: Europe To Add Pfizer/BioNTech To COVID-19 Vaccines Supply Roster

Companies in talks with EU authorities for the supply of at least 200 million initial doses of their mRNA vaccine. Plus, other new partnerships around the world and an India pause for AstraZeneca's contender in line with global decision.

No EUA For COVID-19 Vaccines Prior To Trials Completion, Says India

The Indian regulator says it is not considering emergency use authorization for COVID-19 vaccines before completion of clinical trials, a stand validated by AstraZeneca halting trials of its vaccine candidate due to an adverse event in UK. Meanwhile, India has signed up for Phase III trials of Russia’s vaccine candidate

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

LL1133951

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel